Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research
Pharmaceutics · 21.08.2026 · 18 (8) · 1040
DOI: 10.3390/pharmaceutics18081040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 21.08.2026. Verfasst von Xavier Buin und 5 weiteren Autor:innen. Beteiligte Einrichtung: UnivBrest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 207 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association de transfusion sanguine et de biogénétique Gaétan Saleün, Association Solidarité PLB Muco, Agence Nationale de la Recherche.
Abstract (Originalsprache)
Since the development of the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator in 2012, these therapies have revolutionized patients’ health. They are now the most effective treatment for people with cystic fibrosis (pwCF). In fact, elexacaftor/tezacaftor/ivacaftor and vanzacaftor/tezacaftor/deutivacaftor, the latest combination therapies consisting of a CFTR potentiator and two CFTR correctors, improved lung function by 14% in pwCF. Other modulator therapies targeting CFTR mRNA and/or protein are currently under preclinical/clinical investigation. However, due to the variant-specific nature of these therapies, about 10% of pwCF in Europe remains without effective treatment, and many treated pwCF experience various adverse events such as headaches, infections, hepatotoxicity, hypertension, and depression. Therefore, mutation-agnostic strategies such as gene therapy are needed. They could expand treatment eligibility for all pwCF and improve outcomes. In fact, nucleic acid delivery (e.g., pDNA, mRNA, oligonucleotides, genome editing) or targeting non-CFTR channels to restore ion transport represent promising future additional directions for CF therapy. This review aims to discuss a potential combination between gene therapy approaches and existing modulators to improve treatment eligibility, safety, and efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UnivBrest, Inserm, EFS, UMR 1078, GGB, F-29200 Brest, France.
- Service de Génétique Médicale et de Biologie de la Reproduction, CHU de Brest, F-29200 Brest, France.
- BioISI-Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
- Laboratoire PRéTI, University of Poitiers, F-86022 Poitiers, France.
ORCID-Profile: Xavier Buin, Rosy Ghanem, Margarida Amaral, Tristan Montier
Förderung
- Association de transfusion sanguine et de biogénétique Gaétan Saleün
- Association Solidarité PLB Muco
- Agence Nationale de la Recherche
- Fondation Groupama, Maladies rares
- Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation
- Conseil régional de Bretagne
- ANR-Agence Nationale de la Recherche
- Ministère de l’Enseignement supérieur, de la Recherche et de l’Innovation
Zitieren
APA
Buin, X., Ghanem, R., Pankonien, I., Becq, F., Amaral, M., & Montier, T. (2026). Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research. Pharmaceutics, 18(8), 1040. https://doi.org/10.3390/pharmaceutics18081040
Vancouver
Buin X, Ghanem R, Pankonien I, Becq F, Amaral M, Montier T. Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research. Pharmaceutics. 2026;18(8):1040. doi:10.3390/pharmaceutics18081040
BibTeX
@article{Buin2026,
author = {Buin, Xavier and Ghanem, Rosy and Pankonien, Ines and Becq, Frédéric and Amaral, Margarida and Montier, Tristan},
title = {Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {8},
pages = {1040},
doi = {10.3390/pharmaceutics18081040}
}
EUVIMED